Mangoceuticals, inc. announces closing of $5 million initial public offering

Dallas, tx / accesswire / march 23, 2023 / mangoceuticals, inc. ("mangorx" or the "company") (nasdaq:mgrx), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ed) drug branded "mango," today announced the closing of its initial public offering of 1,250,000 shares of common stock at a public offering price of $4.00 per share. the total gross proceeds of the offering were $5,000,000, prior to deducting underwriting discounts and commissions and other offering expenses payable by the company.
MGRX Ratings Summary
MGRX Quant Ranking